Jeffrey Cummings Selected Research

Capsules (Microcapsules)

11/2007	A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.
7/2007	Pharmacokinetic rationale for the rivastigmine patch.
5/2007	A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey Cummings Research Topics

Disease

78	Alzheimer Disease (Alzheimer's Disease) 04/2024 - 05/2007
30	Dementia (Dementias) 04/2024 - 04/2007
13	Cognitive Dysfunction 02/2024 - 06/2007
10	Disease Progression 04/2024 - 08/2011
10	Parkinson Disease (Parkinson's Disease) 04/2024 - 07/2007
9	Neurodegenerative Diseases (Neurodegenerative Disease) 04/2024 - 01/2015
8	Psychotic Disorders (Schizoaffective Disorder) 04/2024 - 04/2007
6	Hallucinations (Hallucination) 04/2024 - 01/2010
6	Neoplasms (Cancer) 05/2015 - 06/2000
6	Colonic Neoplasms (Colon Cancer) 03/2008 - 02/2002
4	Vomiting 11/2007 - 05/2007
4	Nausea 11/2007 - 05/2007
3	Amyloid Plaque 11/2022 - 01/2008
2	Inflammation (Inflammations) 04/2024 - 01/2020
2	COVID-19 12/2023 - 01/2023
2	Frontotemporal Dementia (Semantic Dementia) 01/2018 - 03/2010
2	Atrophy 01/2015 - 01/2015
2	Colorectal Neoplasms (Colorectal Cancer) 05/2006 - 02/2002
1	Pain (Aches) 08/2023
1	Schizophrenia (Dementia Praecox) 01/2023
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2023
1	Nervous System Diseases (Neurological Disorders) 01/2023
1	Central Nervous System Diseases (CNS Diseases) 01/2023
1	Hypertension (High Blood Pressure) 01/2023
1	Type 2 Diabetes Mellitus (MODY) 10/2022
1	Sleep Wake Disorders 01/2020
1	Neurocognitive Disorders (Clerambault Syndrome) 01/2020
1	Depressive Disorder (Melancholia) 01/2019
1	Urinary Tract Infections (Urinary Tract Infection) 01/2018
1	Neurobehavioral Manifestations 09/2017
1	Prostatic Neoplasms (Prostate Cancer) 03/2014
1	Protein Deficiency 03/2013
1	Neuroinflammatory Diseases 03/2013

Drug/Important Bio-Agent (IBA)

25	Biomarkers (Surrogate Marker)IBA 01/2024 - 03/2008
16	Amyloid (Amyloid Fibrils)IBA 04/2024 - 07/2011
9	Donepezil (Aricept)FDA LinkGeneric 01/2022 - 01/2009
7	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2018 - 07/2007
7	Rivastigmine (Exelon)FDA LinkGeneric 09/2013 - 05/2007
6	Antipsychotic Agents (Antipsychotics)IBA 12/2023 - 06/2008
6	Proteins (Proteins, Gene)FDA Link 10/2022 - 12/2003
5	Cholinergic Agents (Cholinergics)IBA 01/2018 - 06/2007
4	pimavanserinIBA 04/2024 - 02/2014
3	Sildenafil Citrate (Viagra)FDA Link 01/2024 - 12/2021
3	lecanemabIBA 01/2024 - 05/2023
3	aducanumabIBA 11/2023 - 01/2021
3	Monoclonal AntibodiesIBA 11/2023 - 11/2022
3	Capsules (Microcapsules)IBA 11/2007 - 05/2007
3	Irinotecan (Camptosar)FDA LinkGeneric 05/2006 - 02/2002
3	NU-ICRF 505IBA 05/2006 - 02/2002
3	Topoisomerase I InhibitorsIBA 01/2004 - 02/2002
2	Risperidone (Risperdal Consta)FDA LinkGeneric 01/2022 - 01/2017
2	Memantine (Namenda)FDA Link 01/2022 - 02/2011
2	Galantamine (Galanthamine)FDA LinkGeneric 01/2022 - 01/2017
2	Apolipoproteins E (ApoE)IBA 01/2021 - 08/2009
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2015
2	N2- ((2S)- 2- (3,5- difluorophenyl)- 2- hydroxyethanoyl)- N1- ((7S)- 5- methyl- 6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- L- alaninamideIBA 01/2015 - 11/2010
2	Amyloid beta-PeptidesIBA 01/2015 - 01/2015
2	ProgranulinsIBA 03/2013 - 03/2010
2	ApolipoproteinsIBA 08/2009 - 01/2008
2	Uridine Diphosphate (UDP)IBA 01/2004 - 12/2003
1	Neurotransmitter Receptors (Neurotransmitter Receptor)IBA 04/2024
1	brexpiprazoleIBA 04/2024
1	VaccinesIBA 08/2023
1	Telmisartan (Micardis)FDA Link 01/2023
1	serotonin 6 receptorIBA 01/2023
1	gantenerumabIBA 11/2022
1	Insulin (Novolin)FDA Link 10/2022
1	Pioglitazone (Actos)FDA Link 10/2022
1	SecretagoguesIBA 10/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 10/2022
1	Glipizide (Glucotrol)FDA LinkGeneric 10/2022
1	RNA (Ribonucleic Acid)IBA 10/2021
1	rasagiline (Azilect)FDA Link 01/2021
1	Monoamine Oxidase (MAO)IBA 01/2021
1	Complement System Proteins (Complement)IBA 01/2020
1	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA 01/2019
1	Antidepressive Agents (Antidepressants)IBA 01/2019
1	AcidsIBA 01/2019
1	5-HT2A Serotonin Receptor (5 HT2A Receptor)IBA 01/2018
1	6-fluoro-6-desoxyoxymorphone (FOXY)IBA 01/2018
1	TabletsIBA 01/2018
1	Oxytocin (Pitocin)FDA LinkGeneric 01/2018
1	AZD3965IBA 05/2015
1	Indicators and Reagents (Reagents)IBA 01/2015
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2015
1	solanezumabIBA 01/2015
1	Androgen Receptors (Androgen Receptor)IBA 03/2014
1	AZD3514IBA 03/2014
1	N- ((2- (4'- (2- (methylsulfonyl)amino)ethyl)(1,1'- biphenyl)- 4- yl)propyl)- 2- propanesulfonamideIBA 05/2013
1	propionic acid (potassium propionate)IBA 05/2013
1	tau Proteins (tau Protein)IBA 03/2013
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 03/2012
1	Nootropic Agents (Nootropics)IBA 03/2012
1	Neurotransmitter Agents (Neurotransmitter)IBA 03/2012

Therapy/Procedure

30	Therapeutics 04/2024 - 03/2002
14	Activities of Daily Living (ADL) 02/2024 - 11/2007
6	Home Nursing (Nursing, Home) 04/2024 - 08/2009
2	Drug Therapy (Chemotherapy) 05/2006 - 12/2003
1	Long-Term Care 02/2024
1	Institutionalization (Institutionalized Persons) 02/2024